Abstract
Benfluorex, an amphetamine derivative, was marketed as an adjunctive drug for patients with hypertriglyceridemia or diabetes with overweight. We describe here 5 cases of pulmonary arterial hypertension (PAH) associated to a treatment with this drug and notified to the Midi-Pyrénées Pharmacovigilance Centre. All cases are women, exposed to benfluorex during at least 3 years. In most of cases, benfluorex was used off-licence, for overweight.
© 2011 Société Française de Pharmacologie et de Thérapeutique.
MeSH terms
-
Adult
-
Aged
-
Appetite Depressants / adverse effects*
-
Calcium Channel Blockers / therapeutic use
-
Diltiazem / therapeutic use
-
Diuretics / therapeutic use
-
Dyspnea / chemically induced
-
Familial Primary Pulmonary Hypertension
-
Female
-
Fenfluramine / adverse effects
-
Fenfluramine / analogs & derivatives*
-
Furosemide / therapeutic use
-
Humans
-
Hypertension, Pulmonary / chemically induced*
-
Hypertension, Pulmonary / therapy
-
Hypolipidemic Agents / adverse effects*
-
Middle Aged
-
Mitral Valve Insufficiency / complications
-
Mitral Valve Insufficiency / surgery
-
Obesity / complications
-
Obesity / drug therapy
-
Oxygen / therapeutic use
-
Sleep Apnea Syndromes / complications
Substances
-
Appetite Depressants
-
Calcium Channel Blockers
-
Diuretics
-
Hypolipidemic Agents
-
Fenfluramine
-
benfluorex
-
Furosemide
-
Diltiazem
-
Oxygen